JP2008540554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540554A5 JP2008540554A5 JP2008511312A JP2008511312A JP2008540554A5 JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5 JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- group
- hydrogen atom
- alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- 238000009167 androgen deprivation therapy Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002710 gonadal effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68091105P | 2005-05-13 | 2005-05-13 | |
| US60/680,911 | 2005-05-13 | ||
| PCT/US2006/018061 WO2006124447A2 (en) | 2005-05-13 | 2006-05-10 | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540554A JP2008540554A (ja) | 2008-11-20 |
| JP2008540554A5 true JP2008540554A5 (enExample) | 2009-06-25 |
| JP5089578B2 JP5089578B2 (ja) | 2012-12-05 |
Family
ID=37057376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511312A Expired - Fee Related JP5089578B2 (ja) | 2005-05-13 | 2006-05-10 | 選択的なアンドロゲン受容体調節物質としての置換型ｎ−アリールピロリジン |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7807691B2 (enExample) |
| EP (1) | EP1891038B1 (enExample) |
| JP (1) | JP5089578B2 (enExample) |
| CN (1) | CN101175747B (enExample) |
| AT (1) | ATE412647T1 (enExample) |
| AU (1) | AU2006247738A1 (enExample) |
| BR (1) | BRPI0610183A2 (enExample) |
| CA (1) | CA2608419A1 (enExample) |
| CY (1) | CY1108690T1 (enExample) |
| DE (1) | DE602006003432D1 (enExample) |
| DK (1) | DK1891038T3 (enExample) |
| ES (1) | ES2314922T3 (enExample) |
| MX (1) | MX2007014053A (enExample) |
| PL (1) | PL1891038T3 (enExample) |
| PT (1) | PT1891038E (enExample) |
| SI (1) | SI1891038T1 (enExample) |
| WO (1) | WO2006124447A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1911743B8 (en) * | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| US8013008B2 (en) | 2006-11-30 | 2011-09-06 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| CA2695852C (en) | 2007-08-07 | 2017-01-03 | Takeda Pharmaceutical Company Limited | Cyclic amine compounds |
| DK2222636T3 (da) | 2007-12-21 | 2013-06-03 | Ligand Pharm Inc | Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf |
| BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
| WO2009133861A1 (ja) * | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| DK2568806T3 (en) | 2010-05-12 | 2016-08-15 | Radius Health Inc | therapy Programs |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| EP2621901B1 (en) | 2010-09-28 | 2015-07-29 | Radius Health, Inc | Selective androgen receptor modulators |
| EA201391230A1 (ru) * | 2011-02-25 | 2014-01-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов trk |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| MX2015005949A (es) * | 2012-11-16 | 2015-09-08 | Biocryst Pharm Inc | Nucleosidos que contienen aza-azucar antiviral. |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| SG11201811225RA (en) | 2016-06-22 | 2019-01-30 | Radius Health Inc | Ar+ breast cancer treatment methods |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| AU2019271129B2 (en) | 2018-05-14 | 2023-03-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3098628A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| AU2019297421B2 (en) | 2018-07-04 | 2024-08-29 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
| RS64321B1 (sr) | 2018-10-05 | 2023-08-31 | Forma Therapeutics Inc | Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
| CA3128510A1 (en) | 2019-02-12 | 2020-08-20 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| EP3956309A4 (en) | 2019-04-19 | 2023-06-07 | Ligand Pharmaceuticals Inc. | CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND |
| WO2020232119A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2021098810A1 (zh) * | 2019-11-20 | 2021-05-27 | 南京明德新药研发有限公司 | 用作选择性雄激素受体调节剂的化合物 |
| WO2022204184A1 (en) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2025160286A1 (en) * | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2671348B1 (fr) * | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| US7649001B2 (en) * | 2002-08-12 | 2010-01-19 | Takeda Pharmaceutical Company Limited | Fused benzene derivative and use |
| WO2004037784A2 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Pyrrolidones with anti-hiv activity |
| EP1654221A2 (en) | 2003-06-10 | 2006-05-10 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
-
2006
- 2006-05-10 AT AT06759481T patent/ATE412647T1/de active
- 2006-05-10 BR BRPI0610183-6A patent/BRPI0610183A2/pt not_active IP Right Cessation
- 2006-05-10 SI SI200630177T patent/SI1891038T1/sl unknown
- 2006-05-10 PL PL06759481T patent/PL1891038T3/pl unknown
- 2006-05-10 CA CA002608419A patent/CA2608419A1/en not_active Abandoned
- 2006-05-10 WO PCT/US2006/018061 patent/WO2006124447A2/en not_active Ceased
- 2006-05-10 ES ES06759481T patent/ES2314922T3/es active Active
- 2006-05-10 JP JP2008511312A patent/JP5089578B2/ja not_active Expired - Fee Related
- 2006-05-10 PT PT06759481T patent/PT1891038E/pt unknown
- 2006-05-10 CN CN2006800165544A patent/CN101175747B/zh not_active Expired - Fee Related
- 2006-05-10 US US11/913,710 patent/US7807691B2/en not_active Expired - Fee Related
- 2006-05-10 MX MX2007014053A patent/MX2007014053A/es active IP Right Grant
- 2006-05-10 DK DK06759481T patent/DK1891038T3/da active
- 2006-05-10 DE DE602006003432T patent/DE602006003432D1/de active Active
- 2006-05-10 AU AU2006247738A patent/AU2006247738A1/en not_active Abandoned
- 2006-05-10 EP EP06759481A patent/EP1891038B1/en not_active Not-in-force
-
2009
- 2009-01-09 CY CY20091100016T patent/CY1108690T1/el unknown